NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Becker, Pamela S.; Griffiths, Elizabeth A.; Alwan, Laura; Bachiashvili, Kimo; Brown, Anna M.; Cool, Rita; Curtin, Peter T.; Dinner, Shira; Gojo, Ivana; Hicks, Ashley; Kallam, Avyakta; Kidwai, Wajih Zaheer; Kloth, Dwight D.; Kraut, Eric H.; Landsburg, Daniel J.; Lyman, Gary H.; Miller, Ryan; Mukherjee, Sudipto; Patel, Shiven B.; Perez, Lia; Poust, Adam; Rampal, Raajit K.; Rosovsky, Rachel; Roy, Vivek; Rugo, Hope S.; Shayani, Sepideh; Vasu, Sumithira; Wadleigh, Martha; Westbrook, K C; Westervelt, Peter; Burns, Jennifer L.; Keller, Jennifer; Pluchino, Lenora A.

doi:10.6004/jnccn.2020.0002

Cited by 85 publications

(97 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In clinical practice, preventive measures for subjects undergoing systemic anti-cancer treatment are commonly implemented, as serologic screening for certain chronic infections (e.g. hepatitis B [HBV] and C virus [HCV]), and pneumococcal and/or seasonal flu vaccinations (Ariza-Heredia and Chemaly, 2015) Other measures commonly adopted consist in the use of granulocyte colony stimulating factors (G-CSF) and antibiotics for chemotherapy induced neutropenia, either in the prophylactic or therapeutic setting (Becker et al, 2020).…”

Section: Immune System and Cancermentioning

confidence: 99%

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients

Indini

Rijavec

Ghidini

et al. 2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Immune System and Cancermentioning

confidence: 99%

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients

Indini

Rijavec

Ghidini

et al. 2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…Filgrastim, tbo-filgrastim, filgrastim-sndz, or filgrastim-aafi may be administered in the therapeutic setting at a daily dose of 5 mcg/kg. Treatment should continue through postnadir recovery [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment of life-threatening acute osteomyelitis of the jaw during chemotherapy: a case report

Jung

Kim

Park

et al. 2020

J Dent Anesth Pain Med

View full text Add to dashboard Cite

Oral and maxillofacial infection is a common complication in patients undergoing chemotherapy. The treatment of oral diseases in such patients differs from that administered to healthy patients. This paper reports a case of acute osteomyelitis of odontogenic origin following a recent chemotherapy session. The patient's condition was life-threatening because of neutropenic fever and sepsis that developed during the inpatient supportive care. However, the patient showed prompt recovery within 40 days following the use of appropriate antibiotics and routine dressing, without the requirement for surgical treatment, except tooth extraction. As seen in this case, patients undergoing chemotherapy are more susceptible to rapid progression of infections in the oral and maxillofacial areas. Therefore, accurate diagnosis through prompt clinical and radiological examination, identification of the extent of infection, and assessment of the patient's immune system are crucial for favorable outcomes. It is also necessary to eliminate the source of infection through appropriate administration of antibiotics. In particular, a broad-spectrum antibiotic with anti-pneumococcal activity is essential. Proper antibiotic administration and wound dressing are essential for infection control. Furthermore, close consultation with a hemato-oncologist is necessary for effective infection management based on the professional evaluation of patients' immune mechanisms.

show abstract

“…It has been shown to play an important role in the survival and differentiation of neutrophil granulocytes and their progenitors, 5,6 increase in response to bacterial infection and the cell‐mediated immune response for emergency granulocyte production, 6‐8 and enhance the effector functions of mature neutrophils 9,10 . Consequently, G‐CSF is used for prophylaxis of neutropenia and/or febrile neutropenia and as one of the treatments for febrile neutropenia during chemotherapy 3,11,12 …”

Section: Introductionmentioning

confidence: 99%

“…According to studies performed to date, there are no clinically meaningful differences in efficacy and safety between pegfilgrastim (the reference pegylated G‐CSF) and its biosimilars; however, most studies have been conducted in healthy volunteers or patients with solid cancers 15‐19 . No study has compared pegfilgrastim biosimilars with pegfilgrastim in patients with hematologic malignancy, who usually have an intermediate or high risk of febrile neutropenia 3,11,12 …”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim

et al. 2020

View full text Add to dashboard Cite

Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating factor (G‐CSF) analog filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from patients diagnosed with diffuse large B‐cell lymphoma (DLBCL) who were treated with first‐line R‐CHOP chemotherapy and received pegylated G‐CSF for primary prophylaxis. The following pegylated G‐CSFs were analyzed in this study: reference pegfilgrastim (Neulasta®) and two of its biosimilars (tripegfilgrastim; Dulastin® and pegteograstim; Neulapeg®). In total, 296 patients were enrolled. The number of patients with at least one episode of neutropenia during R‐CHOP chemotherapy was the lowest in the reference cohort (pegfilgrastim: 127 of 193 patients, 65.8%; tripegfilgrastim: 64 of 69 patients, 92.8%; pegteograstim: 28 of 34 patients, 82.4%, P < .001). The number of patients with at least one episode of febrile neutropenia was also lowest in the reference cohort (pegfilgrastim: 67 of 193 patients, 34.7%; tripegfilgrastim: 38 of 69 patients, 55.1%; pegteograstim: 16 of 34 patients, 47.1%, P = .009). There were no differences in the duration of neutropenia and febrile neutropenia or treatment outcomes (rate of complete response or relapse and survival). There were no reports of grade 3 or higher adverse events requiring discontinuation of prophylactic pegylated G‐CSF in any group. The safety of the pegfilgrastim biosimilars for prophylactic purposes was comparable to that of the reference pegfilgrastim; however, in terms of their efficacy, the incidence of neutropenia and febrile neutropenia tended to be higher than that when using pegfilgrastim. The clinical relevance of these results in the biosimilar cohorts should be explored.

show abstract

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Cited by 85 publications

References 57 publications

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients

Treatment of life-threatening acute osteomyelitis of the jaw during chemotherapy: a case report

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim

Contact Info

Product

Resources

About